REGENXBIO Inc.
NASDAQ:RGNXBiotechnology
+$0.16 today
- Market cap
- $480.05M
- Beta
- 1.03
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$5.53
Volume 0.70M
Average 1.24M
RGNX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
REGENXBIO Inc.NASDAQ: RGNX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow turns negative
Q1 FY2026 free cash flow was -$77.42M, compared with $32.61M a year earlier. Trailing-twelve-month free cash flow was -$236.4M. Over 3 fiscal years it compounded at -19.0% a year.
Context
- Free cash flow amounted to 74.1% of revenue in FY2025, down 136.5 pp from a year earlier.
- Free cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly free cash flow holds near -$77.42M or moves back toward the trailing-twelve-month quarterly average of -$59.1M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (126.38M) USD
- Year-over-year change
- +28.0%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (126.38M) | +28.0% |
| FY2024 | 2024-12-31 | (175.56M) | +23.1% |
| FY2023 | 2023-12-31 | (228.37M) | +4.1% |
| FY2022 | 2022-12-31 | (238.21M) | -276.8% |
| FY2021 | 2021-12-31 | 134.7M | — |
Free Cash Flow vs competitors
How RGNX compares with its peers on the latest reported figures
- RGNX's LTM Mar 2026 free cash flow of $236.4M is the largest of the 10 companies compared; the peer median is $129.94M.
- Its year-over-year change of +171.9% is the highest of 10, against a peer median of +11.5%.
- Free cash flow amounts to 269.2% of revenue for RGNX, versus a peer median of 251.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $236.4M | +171.9% | -19.0% | 269.2% | |
| LTM Mar 2026 | $179.8M | -15.6% | +0.7% | — | |
| LTM Mar 2026 | $172.86M | +61.1% | +16.0% | — | |
| LTM Mar 2026 | $172.12M | -2.1% | +3.0% | 951.3% | |
| LTM Mar 2026 | $130.06M | -17.1% | +3.6% | 147.4% | |
| LTM Mar 2026 | $129.94M | +14.0% | +108.0% | 356.1% | |
| LTM Jun 2026 | $115.83M | +66.0% | +8.7% | 135.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $98.42M | +11.5% | +21.3% | — |
| LTM Mar 2026 | $59.58M | +14.7% | -4.0% | 1334.3% | |
| LTM Mar 2026 | $2.34M | -97.9% | -24.8% | 2.9% | |
| Peer median (excluding RGNX) | $129.94M | +11.5% | +3.6% | 251.7% | |
Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 127.84M | (280.32M) | (263.49M) | (227.1M) | (193.88M) |
| Depreciation & Amortization | 9.56M | 12.91M | 17.32M | 16.22M | 15.62M |
| Deferred Income Tax | (1.92M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 38.81M | 40.79M | 40.27M | 38.46M | 34.56M |
| Change in Working Capital | 40.22M | 13.98M | (10.89M) | 5.53M | 11.78M |
| Accounts Receivables | 14.12M | 4.82M | 3.94M | 9.71M | (7.66M) |
| Inventory | 29.3M | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.3M) | 18.79M | (2.79M) | (292K) | (2.28M) |
| Other Working Capital | (899K) | (9.64M) | (12.03M) | (3.88M) | 21.73M |
| Other Non-Cash Items | 4.36M | 5.16M | (1.61M) | (6.23M) | 7.96M |
| Operating Cash Flow | 218.88M | (207.49M) | (218.41M) | (173.13M) | (123.96M) |
| Capital Expenditures | (84.18M) | (30.72M) | (9.96M) | (2.44M) | (2.41M) |
| Acquisitions (Net) | (4.99M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (498.14M) | (184.88M) | (86.56M) | (190.14M) | (332.63M) |
| Sales of Investments | 175.68M | 203.67M | 287.47M | 290.24M | 319.11M |
| Other Investing Activities | 4.99M | 0 | 0 | 5.78M | 62K |
| Investing Cash Flow | (406.64M) | (11.93M) | 190.94M | 103.45M | (15.87M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 218.21M | 1.74M | 6.7M | 131.07M | 1.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 1.19M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22.96M) | (30.58M) | (41.67M) | (39.58M) | 115.76M |
| Financing Cash Flow | 195.25M | (28.84M) | (34.97M) | 92.68M | 116.77M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.48M | (248.26M) | (62.43M) | 23M | (23.06M) |
| Free Cash Flow | 134.7M | (238.21M) | (228.37M) | (175.56M) | (126.38M) |
REGENXBIO Inc.
NASDAQ:RGNX
Intrinsic Alpha fair value
Locked
Current Price
$7.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.